Experiencing weight regain (≥ 20% weight from nadir) after achieving clinically successful weight loss.
Willing to have a TORe procedure for the treatment of weight regain.
BMI between 30 and 50 kg/m2, inclusive.
GJA diameter ≥ 20 mm, confirmed either during a
Screening EGD completed ≤ 60 days from study procedure or
EGD performed immediately prior to the TORe procedure.
Anatomically accepting of the procedure, including a pouch size that will not require reduction at the time of treatment (pouch that is shorter than 6 cm in length).
Agrees not to take additional over the counter or prescribed weight loss supplements / medications (including incretins) during the first 6 months of the study.
Is on a stable dose of anti-diabetic medication for three months with no anticipated changes during the first 6 months of the study.
Agrees to the follow-up requirements of the study and is able to read, understand, and sign a written Informed Consent Form to participate in the study.
Meets the indications for TORe procedure with OverStitch™ Endoscopic Suturing System.
You may not be if
Current use or use within the three months prior to the baseline visit of over the counter or prescribed weight loss supplements / medications (including incretins).
Current or planned management of Type 2 Diabetes with incretin medications.
Inability or unwillingness to comply with assigned treatment or protocol requirements related to visits.
Investigator's medical judgement that the subject is not a candidate for the TORe procedure.
Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding in the next two years.
